At this year’s ISPOR, Precision Xtract’s Larry Blandford and Precision Health Economics’ Jason Shafrin met with BioPharm Insights to illuminate the importance of shifting to value-based assessment and examine reasons why US payers are slow to adopt the model.
To read the full article, please click below.